<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845425</url>
  </required_header>
  <id_info>
    <org_study_id>189/2021/Oss/AOUBo</org_study_id>
    <nct_id>NCT04845425</nct_id>
  </id_info>
  <brief_title>Analysis of miRNA Expression in Endometrial Cancer</brief_title>
  <acronym>MIRCE</acronym>
  <official_title>Identification of miRNAs in Endometrial Cancer as Novel Diagnostic and Prognostic Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TCGA project identified four distinct prognostic groups of endometrial carcinoma (EC)&#xD;
      based on molecular alterations: (i) the ultramutated subtype that encompasses POLE mutated&#xD;
      (POLE) cases; (ii) the hypermutated subtype, characterized by MisMatch Repair deficiency&#xD;
      (MMRd); (iii) the copy-number high subtype, with p53 abnormal/mutated features (p53abn); (iv)&#xD;
      the copy-number low subtype, known as No Specific Molecular Profile (NSMP). Although the&#xD;
      prognostic value of TCGA molecular classification, NSMP carcinomas present a wide variability&#xD;
      in molecular alterations and biological aggressiveness. Given that the study aims to evaluate&#xD;
      the miRNA expression profile to identify novel potential biomarkers to better stratify the EC&#xD;
      patients, taking into account the molecular status&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of miRNA expression based on the 4 molecular groups</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate miRNA expression based on the 4 molecular groups recently identified</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Integration of molecular results with clinico-pathological data</measure>
    <time_frame>1 year</time_frame>
    <description>Integration of molecular results with clinico-pathological data</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Endometrial Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        women with endometrial cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt;18yo&#xD;
&#xD;
          -  histological diagnosis of endometrial cancer&#xD;
&#xD;
          -  tumor resection&#xD;
&#xD;
          -  patient's informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with other neoplasia within the last 5 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Myriam Perrone</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS- Azienda Ospedaliera-Universitaria di Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS- Azienda Ospedaliera-Universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <state>Bo</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Anna Myriam Perrone</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <keyword>miRNA</keyword>
  <keyword>microRNA</keyword>
  <keyword>TGCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

